Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals
AssigneeThe Regents of the University of California
InventorsSteven M. Dubinett, Robert M. Strieter, Sherven Sharma, Raj K. Batra
Life of this patent
Estimating the term…
Abstract
The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (SLC) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an SLC to the mammal. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids.
Claims32
A method of effecting an increase in the expression of Interferon-γ (IFN-γ) polypeptides and a decrease in the expression of Transforming Growth Factor-β (TGF-β) polypeptides in a population of syngeneic mammalian cells including CD8 positive T cells, CD4 positive T cells, Antigen Presenting Cells and tumor cells comprising exposing the population of cells to an amount of secondary lymphoid tissue chemokine (SLC) polypeptide sufficient to inhibit the growth of the tumor cells.
A method of inhibiting the growth of spontaneous mammalian cancer cells in a population of syngeneic CD8 positive T cells, CD4 positive T cells and Antigen Presenting Cells comprising exposing the population of cells to an amount of secondary lymphoid tissue chemokine (SLC) polypeptide sufficient to inhibit the growth of the cancer cells.
A method of inhibiting the growth of cancer cells in a mammal comprising administering secondary lymphoid tissue chemokine (SLC) to the mammal;
- wherein the SLC is administered to the mammal by transducing the cells of the mammal with a vector having a polynucleotide encoding the SLC shown in SEQ ID NO:
- 1 so that the transduced cells express the SLC polypeptide in an amount sufficient to inhibit the growth of the cancer cells.
A method of treating a syngeneic cancer in a mammalian subject comprising administering a therapeutically effective amount of an SLC to the subject.
A method of attracting a T lymphocyte or a mature host dendritic cell to a site of a syngeneic tumor in a mammal comprising the steps of:
- (a) obtaining a dendritic cell from the mammal;
- (b) introducing an exogenous polynucleotide encoding secondary lymphoid tissue chemokine as shown in SEQ ID NO:
- 1 into the dendritic cell so that the cell expresses the secondary lymphoid tissue chemokine;
- and
- (c) placing the dendritic cell generated in step (b) at the site of the syngeneic tumor in the mammal;
- wherein the secondary lymphoid tissue chemokine expressed by the dendritic cell generated in step (b) attracts the T lymphocyte or the mature host dendritic cell to the site of the syngeneic tumor in the mammal.
Dependencies are inferred from the claim text.